Lumos Pharma Inc. Stock News

The following slide deck was published by Lumos Pharma, Inc. in conjunction with their 2020 Q2 earnings call..

* Lumos Pharma sells Priority Review Voucher (PRV), valued at $100 million - Lumos Pharma to receive $60 million for its 60% interest in PRV * Lumos Pharma reaffirms its expectation of the initiation

Lumos Pharma, Inc. (NASDAQ:LUMO) Q2 2020 Earnings Conference Call August 13, 2020 4:30 p.m.

Biotech stocks advanced in the week ended Aug. 7, buoyed by multiple catalysts. Aside from the broader market strength, mostly positive earnings and continuing coronavirus...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Lumos Pharma

This year’s virtual Intellisight® Investor Conference on Aug. 12 will showcase a variety of companies and compelling investment stories.

AUSTIN, Texas, July 28, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will report

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 27) Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) Bio-Rad Laboratories, Inc. Class B Common Stock (NYSE: BIO)...

AUSTIN, Texas, July 27, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced that it has ent

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F

- Lumos Pharma expects to initiate its Phase 2b LUM-201 trial in Pediatric Growth Hormone Deficiency (PGHD) prior to the end of 2020 - Additional non-dilutive funds.

AUSTIN, Texas, May 27, 2020 -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced that the.

Lumos Pharma, Inc. (LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will report its first quarter 2020 financial results after market cl

Lumos Pharma, Inc. (LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that Aaron Schuchart will be joining the company as Chief Business Officer st